Roche Holding AG (RHHBY)

Roche Backs Full-Year View as First-Half Sales Rise

Roche confirms full year targets as first-half sales fall

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens

The Hanover Announces CEO Succession Plan: John C. Roche to Retire as President and CEO at the End of 2026; Chief Operating Officer Richard W.

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

EXEL Down on Colorectal Cancer Study Data on Zanzalintinib

U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche

FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL

FDA approves first generic version of Roche's flu drug

JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer

Nurix Therapeutics Deal With Roche Is Worth Betting On